SCHEMBL29772230

SCHEMBL29772230

CSCO[C@@H]1[C@@H]2O[Si](C(C)C)(C(C)C)O[Si](C(C)C)(C(C)C)OC[C@H]2O[C@H]1n1cnc2c(NC(=O)c3ccccc3)ncnc21

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PRMT6 Q96LA8 1/20 0.42
▸ PDE4A P27815 2/20 0.40
▸ PDE4D Q08499 2/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ HTR1A P08908 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ ADRB3 P13945 1/20 0.40
▸ PTGS2 P35354 1/20 0.40
▸ PDE3A Q14432 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ RXFP1 Q9HBX9 1/20 0.40
▸ P2RY12 Q9H244 4/20 0.38
▸ PDE4B Q07343 1/20 0.38
▸ PDE4C Q08493 1/20 0.38
▸ ADORA2A P29274 2/20 0.37
▸ ADORA2B P29275 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19500434 1.00 PRMT6 (0.42) PRMT6PDE4APDE4DCYP1A2HTR1A
SCHEMBL19509704 1.00 PRMT6 (0.42) PRMT6PDE4APDE4DCYP1A2HTR1A
SCHEMBL25966452 0.89 PRMT6 (0.42) PRMT6PDE4APDE4DCYP1A2HTR1A
SCHEMBL29827355 0.88 PRMT6 (0.41) PRMT6PDE4APDE4DCYP1A2HTR1A
SCHEMBL23042726 0.87 PRMT6 (0.43) PRMT6PDE4APDE4DCYP1A2HTR1A
SCHEMBL26238542 0.87 PRMT6 (0.43) PRMT6PDE4APDE4DCYP1A2HTR1A
SCHEMBL29772226 0.87 PRMT6 (0.43) PRMT6PDE4APDE4DCYP1A2HTR1A
SCHEMBL1970429 0.87 PDE4A (0.38) PDE4APDE4DCYP1A2HTR1ACYP2D6
SCHEMBL30773491 0.87 PRMT6 (0.40) PRMT6PDE4APDE4DCYP1A2HTR1A
SCHEMBL5507719 0.87 PRMT6 (0.41) PRMT6PDE4APDE4DCYP1A2HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4622982-A1 METHODS OF SYNTHESIZING A TARGETING LIGAND-CONJUGATED NUCLEOTIDE PHOSPHORAMIDITE Eli Lilly and Company (US) 2025-10-01 — — EP claimed
WO-2024112877-A1 METHODS OF SYNTHESIZING A TARGETING LIGAND-CONJUGATED NUCLEOTIDE PHOSPHORAMIDITE ELI LILLY AND COMPANY (US) 2024-05-30 — — WO claimed
EP-4622982-A1 METHODS OF SYNTHESIZING A TARGETING LIGAND-CONJUGATED NUCLEOTIDE PHOSPHORAMIDITE Eli Lilly and Company (US) 2025-10-01 — — EP disclosed
WO-2024112877-A1 METHODS OF SYNTHESIZING A TARGETING LIGAND-CONJUGATED NUCLEOTIDE PHOSPHORAMIDITE ELI LILLY AND COMPANY (US) 2024-05-30 — — WO disclosed
EP-4021915-A1 LIGAND-2'-MODIFIED NUCLEIC ACIDS, SYNTHESIS THEREOF AND INTERMEDIATE COMPOUNDS THEREOF Dicerna Pharmaceuticals, Inc. (US) 2022-07-06 — — EP disclosed
Send feedback